81 related articles for article (PubMed ID: 23384900)
1. [Clinical features and prognostic analysis of mantle cell lymphoma].
Bao WY; Wang Y; Hu XM; Li JM; Shen ZX; Zhao WL
Zhonghua Xue Ye Xue Za Zhi; 2012 Oct; 33(10):814-8. PubMed ID: 23384900
[TBL] [Abstract][Full Text] [Related]
2. [The clinical features, therapeutic effects and prognosis of mantle cell lymphoma].
Zhang HX; Xu J; Liu T; Xu CG
Zhonghua Xue Ye Xue Za Zhi; 2011 Apr; 32(4):231-5. PubMed ID: 21569704
[TBL] [Abstract][Full Text] [Related]
3. [Clinical analysis of 140 cases of mantle cell lymphoma].
Hu MW; Lou YJ; Yang M; Wang HF; Wang L; Jin J
Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):390-395. PubMed ID: 29860768
[No Abstract] [Full Text] [Related]
4. Treatment of older patients with mantle-cell lymphoma.
Kluin-Nelemans HC; Hoster E; Hermine O; Walewski J; Trneny M; Geisler CH; Stilgenbauer S; Thieblemont C; Vehling-Kaiser U; Doorduijn JK; Coiffier B; Forstpointner R; Tilly H; Kanz L; Feugier P; Szymczyk M; Hallek M; Kremers S; Lepeu G; Sanhes L; Zijlstra JM; Bouabdallah R; Lugtenburg PJ; Macro M; Pfreundschuh M; Procházka V; Di Raimondo F; Ribrag V; Uppenkamp M; André M; Klapper W; Hiddemann W; Unterhalt M; Dreyling MH
N Engl J Med; 2012 Aug; 367(6):520-31. PubMed ID: 22873532
[TBL] [Abstract][Full Text] [Related]
5. [Clinical features and prognostic analysis of mantle cell lymphoma patients].
Zhou P; Shi Y; He X; Zhou S; Liu P; Dong M; Qin Y; Yang J; Zhang C; Zhou L; Yang S; Gui L
Zhonghua Zhong Liu Za Zhi; 2014 Dec; 36(12):928-32. PubMed ID: 25623769
[TBL] [Abstract][Full Text] [Related]
6. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG).
Lenz G; Dreyling M; Hoster E; Wörmann B; Dührsen U; Metzner B; Eimermacher H; Neubauer A; Wandt H; Steinhauer H; Martin S; Heidemann E; Aldaoud A; Parwaresch R; Hasford J; Unterhalt M; Hiddemann W
J Clin Oncol; 2005 Mar; 23(9):1984-92. PubMed ID: 15668467
[TBL] [Abstract][Full Text] [Related]
7. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation.
Visco C; Finotto S; Zambello R; Paolini R; Menin A; Zanotti R; Zaja F; Semenzato G; Pizzolo G; D'Amore ES; Rodeghiero F
J Clin Oncol; 2013 Apr; 31(11):1442-9. PubMed ID: 23401442
[TBL] [Abstract][Full Text] [Related]
8. [Clinical Characteristics and Outcome of 66 Cases of Mantle Cell Lymphomas].
Wu Y; Wang H; Liu XJ; Wang YY; Zhao WL; Li JM; Shen ZX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Aug; 25(4):1036-1041. PubMed ID: 28823264
[TBL] [Abstract][Full Text] [Related]
9. Mantle cell lymphoma in Thai patients.
Intragumtornchai T; Rojnuckarin P; Sutcharitchan P; Wannakrairot P
J Med Assoc Thai; 2004 Sep; 87(9):1071-5. PubMed ID: 15516008
[TBL] [Abstract][Full Text] [Related]
10. [Analysis of prognostic risk factors in patients with diffuse large B-cell lymphoma].
Yu ZP; Ding JH; Chen BA; Gao C; Wang LL; Chen Z
Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):830-5. PubMed ID: 22339956
[TBL] [Abstract][Full Text] [Related]
11. Mantle cell lymphoma in the ocular adnexal region.
Looi A; Gascoyne RD; Chhanabhai M; Connors JM; Rootman J; White VA
Ophthalmology; 2005 Jan; 112(1):114-9. PubMed ID: 15629830
[TBL] [Abstract][Full Text] [Related]
12. [Clinical Characteristics and Prognosis of 34 Patients with Mantle Cell Lymphoma: A Retrospective Analysis].
Chen XP; Zhao Y; Wang QS; Lv N; Li YH; Jing Y; Yu L
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Dec; 23(6):1601-6. PubMed ID: 26708879
[TBL] [Abstract][Full Text] [Related]
13. Retrospective analysis of 23 cases with peripheral T-cell lymphoma, unspecified: clinical characteristics and outcome.
Zaja F; Russo D; Silvestri F; Fanin R; Damiani D; Infanti L; Salmaso F; Mariuzzi L; Di Loreto C; Baccarani M
Haematologica; 1997; 82(2):171-7. PubMed ID: 9175321
[TBL] [Abstract][Full Text] [Related]
14. Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP.
Sehn LH; Scott DW; Chhanabhai M; Berry B; Ruskova A; Berkahn L; Connors JM; Gascoyne RD
J Clin Oncol; 2011 Apr; 29(11):1452-7. PubMed ID: 21383296
[TBL] [Abstract][Full Text] [Related]
15. Autologous transplantation and management of younger patients with mantle cell lymphoma.
Geisler CH
Best Pract Res Clin Haematol; 2012 Jun; 25(2):211-20. PubMed ID: 22687457
[TBL] [Abstract][Full Text] [Related]
16. [Comparison of the efficiency of CHOP-based regimen with or without high dose consolidation treatment combined with hematopoietic stem cell transplantation in 63 lymphoblastic lymphoma patients].
Qin Y; Shi YK; He XH; Han XH; Zhou SY; Liu P; Yang JL; Yang S; Zhang CG; Dong M; Zhou LQ; Wang JW; Feng FY; Sun Y
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):469-73. PubMed ID: 19950562
[TBL] [Abstract][Full Text] [Related]
17. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
[TBL] [Abstract][Full Text] [Related]
18. Simplified MIPI-B prognostic stratification method can predict the outcome well-retrospective analysis of clinical characteristics and management of newly-diagnosed mantle cell lymphoma patients from China.
He JS; Chen X; Wei GQ; Sun J; Zheng WY; Shi JM; Wu WJ; Zhao Y; Zheng GF; Huang H; Cai Z
Medicine (Baltimore); 2019 Jan; 98(1):e13741. PubMed ID: 30608386
[TBL] [Abstract][Full Text] [Related]
19. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
20. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.
Romaguera JE; Fayad L; Rodriguez MA; Broglio KR; Hagemeister FB; Pro B; McLaughlin P; Younes A; Samaniego F; Goy A; Sarris AH; Dang NH; Wang M; Beasley V; Medeiros LJ; Katz RL; Gagneja H; Samuels BI; Smith TL; Cabanillas FF
J Clin Oncol; 2005 Oct; 23(28):7013-23. PubMed ID: 16145068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
